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Background: Prognostic stratification in heart failure (HF) is crucial to guide clinical management and treatment
decision-making. Currently available models to predict HF outcome have multiple limitations. We developed a
simple risk stratification model, based on routinely available clinical information including comorbidities, the
Cardiac and Comorbid Conditions HF (3C-HF) Score, to predict all-cause 1-year mortality in HF patients.
Methods: We recruited in a cohort study 6274 consecutive HF patients at 24 Cardiology and Internal Medicine
Units in Europe. 2016 subjects formed the derivation cohort and 4258 the validation cohort.We entered informa-
tion on cardiac and comorbid candidate prognostic predictors in amultivariablemodel to predict 1-year outcome.
Results: Median age was 69 years, 35.8% were female, 20.6% had a normal ejection fraction, and 65% had at least
one comorbidity. During 5861 person-years follow-up, 12.1% of the patients met the study end-point of all-
cause death (n=750) or urgent transplantation (n=9). The variables that contributed to outcome prediction,
listed in decreasing discriminating ability, were: New York Heart Association class III–IV, left ventricular ejection
fraction b20%, no beta-blocker, no renin–angiotensin system inhibitor, severe valve heart disease, atrial fibrilla-
tion, diabetes with micro or macroangiopathy, renal dysfunction, anemia, hypertension and older age. The C sta-
tistic for 1-year all-cause mortality was 0.87 for the derivation and 0.82 for the validation cohort.
Conclusions: The 3C-HF score, based on easy-to-obtain cardiac and comorbid conditions and applicable to the 1-
year time span, represents a simple and valuable tool to improve the prognostic stratification of HF patients in
daily practice.© 2011 Elsevier Ireland Ltd. All rights reserved.re – Dipartimento di Medicina
4128 Bergamo Italy. Tel.: +39
M. Senni).
Ltd. All rights reserved.
icting heart failure outcome1. Introduction
Risk assessment in heart failure (HF) is crucial for clinical manage-
ment, treatment decision-making, counseling of patients and their
families, and monitoring the quality of health care. Prognostic strati-
fication is nevertheless a difficult task. Variability in the outcomes offrom cardiac and comorbid conditions: The 3C-HF score, Int J Cardiol
2 M. Senni et al. / International Journal of Cardiology xxx (2011) xxx–xxxHF patients is large, one-year mortality rates range from 5% to 75% in
randomized clinical trials [1,2] and from 11% to 42% in community
studies [3,4]. No single parameter can be expected to reliably predict
prognosis in this markedly heterogeneous population.
The combination of several variables in prognostic models has
emerged as the most appropriate approach to capture the complexity
of the HF syndrome. However, the still imperfect predictive accuracy of
currently available risk stratificationmodels trades offwithmultiple lim-
itations. Most models are based on retrospective or single-centre assess-
ment, or are derived from small series [5–7]. Selection bias is another
issue: many studies included patients from randomized clinical trials or
on the heart transplantwaiting list, did not consider the entire spectrum
of systolic function, or focused on middle-aged patients without comor-
bidities [8–12]. In some instances the clinical relevance or availability of
predictive variables was poor and the statistical approach inadequate.
Until now, no model has gained widespread acceptance. In daily clinical
practice estimates of patient's prognosis are mainly founded on individ-
ual clinician's experience based on some specific prognostic indicators.
We tried to address these limitations in a cohort study, on a large
sample of patients, with a wide range of HF severity and comorbid-
ities, who were enrolled in different settings and episodes of care.
We aimed to develop a simple risk stratification model, based on rou-
tinely available clinical information, in order to predict one-year out-
come in daily practice.Fig. 1. One-year survival free from urgent heart transplantation in the overall study
cohort.2. Methods
2.1. Study population and protocol
We invited 24 Cardiology and Internal Medicine Units to enroll at least 100 HF pa-
tients consecutively seen during a 6- to 12-month period between 2002 and 2006. Par-
ticipating institutions had a minimum yearly volume of >100 HF admissions during
the sampling period and had taken part in registries or surveys on HF.
Prospectively enrolled patients from the first 8 institutions that joined the study
formed the derivation cohort (n=2016), that was used to build the prognostic
model. Subjects recruited at the 16 centres, that accepted to participate later on, con-
stituted the validation cohort (n=4258), that was used to test the prognostic accuracy
of the model. These centres also enrolled a subset of patients retrospectively identified
among those meeting eligibility criteria.
Inclusion criteria were a diagnosis of HF based on symptoms and signs of conges-
tion and objective evidence of cardiac dysfunction at rest [13]. Left ventricular ejection
fraction (LVEF) was measured by echocardiography within 6 months of enrolment. Pa-
tients with HF symptoms and a LVEF≥50% had to show lung congestion by chest X-
ray.
We excluded patients who died during the index admission. Patients with an indi-
cation for any cardiac surgical procedure, other than transplantation, were excluded
because of the independent impact of heart surgery on outcome. Patients with meta-
static cancer were excluded because of their very poor life expectancy independently
of the HF syndrome.
We recruited subjects either at discharge or in the outpatient clinic. For prospec-
tively enrolled subjects, information was gathered at hospital discharge or at the
index outpatient visit. For retrospective enrolment, we reviewed hospital records iden-
tified through a primary diagnosis of HF (ICD-9-CM code 428.xx), as well as outpatient
clinic records of subjects followed-up at different institutions.
We considered clinical, laboratory, and echocardiographic data within the last
6 months prior to enrolment. Existing guidelines were used to define severity of
valve heart disease [14] and optimization of medical treatment [13].
Patients were followed-up at each centre after the index discharge or outpatient
visit (time 0). One-year survival status (the study endpoint) was ascertained locally
by follow-up visits or chart review, telephone interview with the patient, or his/her
family, or primary care physician, or by examination of death certificates. Urgent
heart transplantation, defined as UNOS status 1 [15], was counted as a death. Patients
who underwent elective heart transplantation were censored seven days after the pro-
cedure. Patient follow-up was 100% complete.
Patients expressed their general written consent to the anonymous use of data for
their care and research purposes. Databases for clinical use were authorized at each
centre. Observational studies, where no experimental treatment was evaluated, did
not require a formal review board waiver until 2008 in the European countries,
where the participating centres were located. The authors of this manuscript have cer-
tified that they comply with the Principles of Ethical Publishing in the International
Journal of Cardiology [16].
Data were sent to the Heart Failure Research Centre, Bergamo, Italy for reassess-
ment of completeness and accuracy; periodical queries were issued for missing or in-
consistent information.Please cite this article as: Senni M, et al, Predicting heart failure outcome
(2011), doi:10.1016/j.ijcard.2011.10.0712.2. Statistical analysis
Routinely available established predictors [17] of HF survival were considered for
inclusion in a logistic regression model for the binary indicator of one-year survival
since baseline. It was decided a priori that, in case of statistical significance, an analysis
via Cox proportional hazards model would be performed for confirmation. Whenever
appropriate, before inclusion in model, the predictors were dichotomized on the
basis of clinically significant cut-offs. The patients in the prospective derivation
cohort were iteratively partitioned into two sets. At each iteration, the former set
was used to "train" the model, and the latter to then obtain an unbiased assessment
of predictive performance. This allowed us, on the basis exclusively of the derivation
cohort, to eliminate redundant predictors, and to assess the resulting model in terms
of predictive discrimination via C statistic, i.e., the area under the ROC curve [18] and
Brier score [19].
We also checked for possible centres with an unduly large impact on the estimated
parameters. The model predictive performance was further, and independently,
assessed on the basis of the validation cohort, separately in the following strata of
the cohort: retrospectively and prospectively enrolled, discharged patient or outpa-
tient, Cardiology or Internal Medicine patient, normal or reduced LVEF, eligible for car-
dioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) [20],
device carrier/not carrier at baseline.
To create a practical prognostic score system, the Cardiac and Comorbid Conditions
Heart Failure (3C-HF) score, we multiplied model regression coefficients, corrected by
age effect, by 10 and rounded to the nearest integer [21].
Reliability for abstraction of categorical variables in 204 randomly selected retro-
spective records (11%) was high. Using crude agreement, the interobserver reliability
and the kappa statistic were, respectively, 0.99 and 0.94 (95% CI 0.88–0.99) for chronic
obstructive lung disease, 0.97 and 0.89 (95% CI 0.83–0.95) for complicated diabetes,
0.96 and 0.92 (95% CI 0.83–0.99) for hypertension, and 0.98 and 0.97 (95% CI 0.93–
1.0) for NYHA class III–IV.
Analysis was based on software we developed under R (Version 2.6.0) and SAS
(Version 9.2; SAS Institute Inc, Cary, NC, USA).3. Results
We recruited overall 6274 patients, both in Internal Medicine
(1447, 23%) and Cardiology Units (4827, 77%); 1823 patients (29%)
were enrolled retrospectively and 4451 (71%) prospectively. Quanti-
tative assessment of LVEF was available in 6225 patients (99%). At en-
rolment, 714 patients had a device in place: ICD (n=382, 6%), CRT
(n=122, 2%) or both (n=210, 3%). These figures represented 23%
and 59% of the patients eligible [20] for ICD (n=2541) or CRT
(n=564), respectively; overall 26% of the 2743 subjects (44%) with
an indication for devices had been implanted.
During 5861 person-years follow-up, 12% of the patients met the
study end-point of all-cause mortality (n=750) or urgent heart
transplant (n=9); transplant-free survival is presented in Fig. 1.
The derivation and validation cohorts originally contained 2016
and 4258 patients, respectively. Clinical characteristics of both origi-
nal cohorts are summarized in Table 1. As many as 213 (3%) subjectsfrom cardiac and comorbid conditions: The 3C-HF score, Int J Cardiol
Table 1
Clinical characteristics of the derivation and validation cohorts.
Study cohorts Derivation N. 2016 Validation N. 4258
Female gender 603 (29.9) 1647 (38.7)
Age (years) 68 [58–76] 70 [60–77]
≥2 comorbidities 488 (24.2) 1197 (28)
NYHA class III–IV (n=6247) 677 (33.6) 1420 (33.6)
LVEF% (n=6225) 35 [27–40] 38 [29–50]
LVEF b20% 92 (4.6) 187 (4.4)
LVEF ≥50% 195 (9.7) 1099 (26.1)
No beta blocker 580 (28.8) 1487 (34.9)
No RAS inhibitors 237 (11.8) 749 (17.6)
Severe valve heart disease 233 (11.6) 631 (14.8)
Atrial fibrillation 550 (27.3) 1166 (27.4)
Diabetes with target organ damage 304 (15.1) 813 (19.1)
Chronic kidney dysfunction
(creatinine>176 μmol/L)a (n=6152)
157 (7.8) 394 (9.5)
Serum creatinine (μmol/L) 106 [88–128] 102 [86–131]
Anemia (hemoglobinb11 g/dl)
(n=6205)
190 (9.4) 528 (12.6)
Hemoglobin (mg/dL) 13.6 [12.3–14.7] 13.2 [12–14.5]
Hypertension
(blood pressure≥140/90 mm Hg)
939 (46.6) 1909 (44.9)
Chronic obstructive lung disease
(GOLD guidelines)
302 (15.0) 737 (17.3)
Eligible for device therapy
(ICD and/or CRT)
1117 (55.4) 1626 (38.2)
Carrier of device (ICD and/or CRT)
(% of eligible subjects)
280 (25.1) 434 (26.7)
Deceased/transplanted at 1-year 225 (11.2) 534 (12.5)
3C-HF score (n=6061) 10 [3–20] 12 [4–23]
Data are expressed as number (percentage) or median [interquartile range]. CRT, cardiac
resynchronization therapy; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association; RAS, renin–angiotensin system; target organ damage
includes microangiopathy (retinopathy, neuropathy, nephropathy) or macroangiopathy
(coronary artery disease, peripheral vessel disease).
a Creatinine>2 mg/dl.
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least one of the predictors, which left us with 2012 subjects in the
derivation and 4049 subjects in the validation cohort, for a total of
6061 subjects retained for outcome analysis. Close examination of
the discarded individuals did not raise any suspicion that the missing-
ness could be related to outcome-informative mechanisms, condi-
tionally on the recorded predictors.
Table 2 summarizes the results from the fitting of a logistic regres-
sion model for one-year mortality to the derivation cohort data, using
the entire set of candidate predictors on their original (possiblyTable 2
Candidate predictors of one-year mortality or urgent heart transplant by multivariable
logistic regression.
Variable Odds ratio 95% CI P valuea
Age (per decade increase) 1.13 1.0–1.4 b0.0001
Cardiac variables
NYHA class III–IV 4.09 3.3–5.4 b0.0001
No RAS inhibitors 2.02 1.6–2.4 b0.0001
Severe valve heart disease 2.01 1.6–2.5 b0.0001
No beta blocker 1.58 1.2–1.8 b0.0001
Atrial fibrillation 1.45 1.2–1.7 0.0003
LVEF (per 5 unit increase) 0.96 0.95–0.98 b0.0001
Comorbid conditions
Diabetes with target organ damage 1.48 1.20–1.80 b0.0001
Hemoglobin
(per 0.5 g/dL increase)
0.89 0.84–0.94 b0.0001
Serum creatinine
(per 26 μmol/L increase)
1.03 1.01–1.04 0.0004
Hypertension 0.78 0.6–0.9 0.004
Gender (female) 0.73 0.4–1.2 0.11
Chronic obstructive lung disease 1.20 0.8–1.5 0.09
Device therapy (ICD and/or CRT) 0.78 0.4–1.3 0.21
CI= confidence interval
a Wald's test. For abbreviations see Table 1.
Please cite this article as: Senni M, et al, Predicting heart failure outcome
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regression effect on an odds-ratio scale, together with its correspond-
ing 95% confidence intervals, and the p-value for the null hypothesis
of no effect, according to a univariate Wald's test. The C statistic for
this model using continuous variables was 0.88 (95% CI 0.86 to
0.90). We detected no evidence of interaction between the predictive
variables nor any unduly large impact of the data from a particular
centre on the estimated coefficients.
Bootstrap elimination of redundant variables left us with the set of
variables listed in Table 3, which we consider our final selected, and
recommended, set of predictors. A logistic regression model based
on the combined set of selected predictors was fitted to the entire
derivation cohort. The results from this fitting are summarized in
Table 3, which contains the estimated regression effects, expressed
on an odds-ratio scale, together with the corresponding 95% confi-
dence interval and the relative contribution of each variable to the ad-
ditive 3C-HF score. The predictive performance of additive 3C-HF
score was 0.87 (95% CI 0.86 to 0.88) in the derivation cohort.
Both the logistic regression model and the additive score were
then applied to the validation cohort, avoiding refitting. When
assessed in the validation cohort, the logistic model performance
was 0.83 (95% CI 0.82 to 0.84), while the additive 3C-HF score
achieved a C statistic of 0.82 (95% CI 0.81 to 0.83), with a Brier score
of 0.082. Table 4 summarizes the predictive performance of the addi-
tive 3C-HF score across different strata of the validation cohort.
One-year all-cause mortality and urgent heart transplant rates
with 95% confidence intervals in patient groups based on deciles of
3C-HF score were separately plotted for the derivation and validation
cohorts (Fig. 2).
Kaplan–Meier event-free survival curves by in deciles of 3C-HF
score in the overall population (n=6061) are presented in Fig. 3
(log rank test Pb0.0001). A Web-based calculator (http://www.3chf.
org) has been built up, allowing easy and interactive calculation of in-
dividual patient’s estimated survival, through the logistic regression
model and the additive score.
4. Discussion
In a large, multicentre HF population, enrolled in different clinical
settings, we developed a prognostic model, the 3C-HF score, that
combines cardiac and comorbid conditions commonly present in pa-
tients affected by this syndrome. The score allowed a good separation
of 1-year survivors from non-survivors, with a C statistic of 0.82 in theTable 3
Dichotomized logistic regression model and corresponding points for the additive ver-
sion of the 3C-HF score (http://www.3chf.org).
Variable Odds ratio 95% CI P valuea Points
(additive score)
Age
(per 10 years≥40)
1.03 1.0–1.2 b0.0001 1
Cardiac variables
NYHA class III–IV vs I–II 4.09 3.3–5.4 b0.0001 13
LVEF b20% vs ≥20% 2.77 1.5–4.1 b0.0001 11
No RAS inhibitors 2.01 1.6–2.5 b0.0001 8
Severe valve heart
disease
2.02 1.6–2.4 b0.0001 7
Atrial fibrillation 1.58 1.2–1.8 b0.0001 7
No beta blocker 1.45 1.2–1.7 0.0003 4
Comorbid conditions
Chronic kidney
dysfunction
1.79 1.5–2.1 b0.0001 6
Diabetes with target
organ damage
1.62 1.4–1.8 b0.0001 6
Anemia 1.47 1.2–1.8 0.0011 4
Hypertension 0.78 0.6–0.9 0.0040 −4
CI= confidence interval
a Wald's test. For abbreviations see Table 1.
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Table 4
Performance of the 3C-HF score in the validation cohort across patient subgroups.
Groups N % C statistic
(95% CI)
Brier score P value
Retrospectively enrolled 1736 (42.8) 0.83 (0.81–0.85) 0.06 0.64
Prospectively enrolled 2313 (57.2) 0.82 (0.80–0.83) 0.07 0.72
Cardiology units 2618 (64.6) 0.82 (0.80–0.84) 0.08 0.77
Internal Medicine units 1431 (35.4) 0.85 (0.82–0.88) 0.07 0.67
Left ventricular ejection
fraction b50%
2969 (73.3) 0.82 (0.81–0.83) 0.06 0.79
Left ventricular ejection
fraction ≥50%
1080 (26.6) 0.83 (0.81–0.85) 0.09 0.69
Not eligible for devicea 2526 (62.3) 0.83 (0.82–0.84) 0.08 0.84
Eligible for device 1523 (37.7) 0.84 (0.82–0.86) 0.08 0.55
Eligible for device, not
implanted
1138 (74.7) 0.82 (0.80–0.84) 0.10 0.40
Eligible for device,
implanted
385 (25.3) 0.84 (0.81–0.87) 0.07 0.77
CI= confidence interval
a Device includes ICD and/or CRT.
Fig. 3. Kaplan–Meier analysis of survival free from urgent heart transplant according to
deciles of 3C-HF score in the overall cohort (n=6061); the first 3 deciles (scoreb5)
have been grouped in a single class (log rank Pb0.001). Numbers of patients in score
classes at each time point are shown below the x axis.
4 M. Senni et al. / International Journal of Cardiology xxx (2011) xxx–xxxvalidation sample, the highest among those of previously published
prognostic models, which ranged from 0.69 to 0.76 [5–12]. The 3C-
HF C statistic compares favorably with the most validated cardiovas-
cular risk scoring system, the Framingham Score [22] (0.74 in men
and 0.77 in women).
Currently available HF risk stratification models present important
limitations [5–12,23–25].
The exclusion of elderly patients and comorbidities from risk as-
sessment is a serious drawback, as most community HF patients
have at least one associated disease [26]. In contrast, this multicentre
cohort well represents “real world” HF patients, as seen by cardiolo-
gists or internists, and quite distinct from typical trial patients
[8,9,12]. Subjects were recruited from both Cardiology and Internal
Medicine Units, two out of three had one or more comorbidities,
one third were older than 75 years, a substantial proportion had a
normal LVEF and one-year mortality was comparable to previous HF
community studies and registries [27–30].
The 3C-HF score is the first model validated in a large non-trial HF
population with a normal LVEF (≥50%, 1080 patients, 26.6% of to the
validation cohort to exhibit a good predictive performance ( statistic
0.83). Even when a previously reported cut-off (≥40%, 47.9% of theFig. 2. The graph compares the event rates for the study end-point (all-cause death or
urgent heart transplant) in the derivation (n=2012) and validation (n=4049)
cohorts) by deciles of 3C-HF score. Predicted mortality (central continuous line) with
95% confidence intervals (hatched lines) is plotted against observed mortality (closed
squares) with 95% confidence intervals (vertical bars). The first 3 deciles (score b5,
death rates all b1%) have been grouped in a single class. Histograms in the lower
panel represent the total number of patients (n=6061) in each score class.
Please cite this article as: Senni M, et al, Predicting heart failure outcome
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bly good (0.83). The proportion of subjects with preserved LVEF in
our series and their clinical profile are close to prevalence and charac-
teristics of these patients in community studies. Conversely, in the Se-
attle Heart Failure Model [9], only two of the six study cohorts (9.2%
of subjects) included patients with a LVEF>40%. Moreover, our
score largely outperformed the model developed both from the
CHARM study [8] and from the SENIORS trial [12] (C statistic 0.74
and 0.69, respectively). Despite well-known differences in the clinical
profiles of patients with preserved or reduced LVEF, our score suc-
ceeded in balancing the informative value of each cohort's peculiar
characteristics, as shown by its accurate prediction across the entire
spectrum of ventricular impairment. This result has important impli-
cations for the applicability of the score to unselected patients in the
community [3,27,28].
In order to verify whether the model could be used in future ret-
rospective analyses, we also included patients who were retrospec-
tively identified from each centre database. Model performance
overlapped in this subset (0.82) and in prospectively enrolled (0.83)
subjects.
The variables included in the 3C-HF score were selected for their
ready availability and previously reported prognostic significance. In
a prognostic model, accurate prediction should be balanced against
practicality. In an attempt to maximize predictive performance,
some studies have proposed models that require the collection of ex-
tensive or costly data, which may make them impractical for routine
use. For example, b5% of HF patients undergoes a cardiopulmonary
exercise test [27]; thus, although data on maximal oxygen consump-
tion may increase predictive accuracy, their inclusion in the model
will hamper its use in clinical routine. By restricting to simple, easy-
to-obtain, items, prognostic indices are closer to real practice, have
greater practical value, and may be used in primary care and at the
bedside.
The incorporation of medications into the score is crucial, as drug
therapymay bemodified to improve patient survival. Pharmacological
treatment was generally optimized in the present series, as suggested
by prescription rates of beta-blockers (67%) and renin–angiotensin
system inhibitors (84%), which were close to the recommended tar-
gets in the absence of contraindications. Patients who are not pre-
scribed, or cannot tolerate these drugs because of advanced diseasefrom cardiac and comorbid conditions: The 3C-HF score, Int J Cardiol
5M. Senni et al. / International Journal of Cardiology xxx (2011) xxx–xxxor contraindications, are unsurprisingly at higher risk of death. In this
respect, direct comparison with other scores is not possible as, e.g. in
the Seattle HF Model, beta-blockers and renin–angiotensin system in-
hibitors were not directly included in the model and hazard ratio esti-
mates were based on literature data [9].
Device therapy is increasingly practiced in HF and indications have
changed since our study cohort was enrolled. Although CRT and/or
ICD had been implanted in 59% and 23% of potentially eligible pa-
tients, absolute numbers were very low overall and might account
for the lack of predictive value for device therapy in the model. On
the other hand, these low numbers are consistent with reports from
large unselected series, where the proportion of subjects eligible for
CRT or ICD ranged from 6.8 to 17% and 47% to 51%, respectively
[31]. Potential CRT benefits, such as improvement of ventricular func-
tion, reduction of functional mitral regurgitation, and introduction of
beta-blockers, were indirectly incorporated into the score. Eventual
CRT should prompt a recalculation of the score.
The 3C-HF score stratifies the individual patient risk at one year, a
time span that is critical for treatment choices, such as device therapy,
but still minimizes the potentially larger impact of comorbidities,
rather than cardiac conditions, on outcome. Risk stratification should
be repeated after one year, since in an elderly population comorbid-
ities in particular may change.
The clinical implications of our simple predictive tool are relevant.
Patients should receive care at the level best suited to their individual
needs, to appropriately allocate scarce and costly specialist resources.
Low-risk patients could be routinely managed in primary care, once
the specialist has prescribed the optimized polypharmacy in a stable
patient. Conversely, patients at intermediate risk should receive
more intensive specialist follow-up and be referred for invasive inter-
ventions, when indicated. In subjects at very high risk (score ≥32;
50% one-year mortality) ICD or any surgical treatment may be futile,
and a palliative care approach might be considered instead.5. Limitations
Although large and mainly prospective, our study has several lim-
itations inherent to its observational nature. Selection bias might
have resulted from some characteristics: the centres invited to partic-
ipate were among those with expertise in HF management and each
volunteered to participate, and mostly white and Caucasian patients
were enrolled.
To enhance the applicability of the score to complex real world pa-
tients in whom coronary angiography, mandatory for an accurate as-
certainment of the ischemic aetiology of HF, may be difficult to
perform, we chose not to consider this variable among candidate
predictors.
Both anemia and renal dysfunction, which contribute in a level-
dependent fashion to negative outcomes in HF, may be classified in
different ways. Our clinically consistent cut-offs for hemoglobin and
creatinine did not result in significant loss of predictive ability over
continuous values. Although use of estimated glomerular filtration
rate over creatinine has been advocated to increase accuracy in the
assessment of renal dysfunction, the >176 μmol/L creatinine cut-off
underestimated severe renal dysfunction, as determined by glomeru-
lar filtration rates b30 mL/min*1.73 m2 in only 1.8% of our series.
Our model does not include all variables that may significantly and
independently contribute to outcome. Natriuretic peptides, potentially
useful predictors of outcome, were not yet routinely available in most
centres at the time of the study. However, the evidence that these bio-
markers have prognostic value across the entire spectrum of the HF
population is currently limited [32], in particular amongelderly patients
and those with renal dysfunction, who were both well-represented in
our series. Moreover, the addition of natriuretic peptides to cardiovas-
cular clinical prediction models only modestly improved the C statisticPlease cite this article as: Senni M, et al, Predicting heart failure outcome
(2011), doi:10.1016/j.ijcard.2011.10.071[33]. Further studies are probably needed to evaluate whether adding
BNP can be valuable to improve the predictive value of this score.
6. Conclusions
Estimating prognosis is a key element of HF management. The 3C-HF
score, based on cardiac and comorbid conditions, is easy to obtain, appli-
cable to the 1-year time span, and minimizes the limitations present in
previous models. The score represents a valuable tool for physicians
who are confronted daily with decisions on the type of care to offer and
on the appropriateness of therapeutic interventions. Although good clin-
ical judgment is still of paramount importance, prognostic models should
be included in clinical practice as decisional support tools.
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